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Background: Substance use disorders (SUDs) have been described as a dysfunctional
way to compensate for deficiencies in that person’s underlying attachment system.
Furthermore, the neuropeptide oxytocin (OT), which is a critical component of the
neurobiology of the attachment system, has been shown to effectively reduce addictive
behavior and therefore has been discussed as a potential medication in SUD treatment.
This study investigates variation in peripheral OT plasma levels as a function of exposure to
an attachment-related stimulus in SUD patients compared to healthy controls (HCs).
Methods: A total sample of 48 men, 24 inpatients in maintenance treatment who were
diagnosed with poly-drug use disorder (PUD) and 24 HC, was investigated. A 15-min
exposure to the Adult Attachment Projective Picture System (AAP) was used as an
attachment-related stimulus and coded for attachment status. Blood samples before and
after the AAP-assessment were taken and assayed for OT levels. Variation in baselines
level of OT was examined in relation to the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST), the Adult Attachment-Scale (AAS), and the Brief Symptom
Inventory (BSI).
Results: Following the AAP stimulus controls showed no significant difference in OT levels
elevation from baseline compared to the PUD group’s OT levels. Furthermore, in the PUD
group only OT-baseline-levels may be negatively associated with the AAS subscale
“Comfort with Closeness” and “Anxiety” and lifetime substance use.g September 2020 | Volume 11 | Article 4605061
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Frontiers in Psychiatry | www.frontiersin.orDiscussion: Our results suggest that peripheral OT levels in poly-drug users undergoing
maintenance treatment are not significantly different in responsiveness to an attachment
related stimulus compared to HC. With regard to non-significant tendencies observed in
this study which hint toward decreased OT-reactivity in the PUD group, further research is
needed to explore this hypothesis with increased statistical power.Keywords: attachment, maintenance treatment, poly drug use, oxytocin, substance use disorderINTRODUCTION
Substance use disorders (SUDs) have been characterized as a
compulsive substance use without consideration of the negative
consequences (1) and are increasingly framed as a neurobiological
disorder (2, 3). Currently, the most common form of SUD in
patients undergoing treatment in Austria is poly-drug use disorder
(PUD), with opioids as the primary drug of choice (4), a pattern
which is also found in the majority of SUD patients across Europe
(5). In recent years, increasing number of patients are treated within
maintenance treatment programmes, which have been shown to be
effective treatments by reducing heroin use and risk behaviors as
well as improving health, social and criminal justice outcomes (6).
From a psychodynamic perspective, SUD has been understood
in relation to attachment disorder (7) and as a dysfunctional way of
self-medicating (8). Specifically, insecure attachment has been
linked to increased psychopathology for decades (9). Formed by
early parent-infant interactions, which are gradually imprinted in
neuronal pathways (10, 11), attachment can be understood as a
neurobiological system designed to promote social affiliation and
primary bonding experiences (12, 13). Recent studies indicate a
substantial role of insecure attachment in the etiology of SUDs (14–
16)—among other psychiatric disorders (17). This relationship has
been linked to the influence of attachment styles on the
interpersonal regulation of human emotions particularly fear,
anxiety and hedonic experiences within close relationships (18, 19).
Attachment research across mammalian species has
suggested that the neuropeptide oxytocin (OT) plays a central
role in the neurobiological processes involved in the formation
and maintenance of social bonds (20), interpersonal affect
regulation (14, 21) and parent-child relationships (22–24), but
also protective aggression (25). The OT-system in humans is
associated with brain regions including the amygdala,
paraventricular nucleus (PVN), supraoptic nucleus (SON),
ventral pallidum (VP), ventromedial nucleus of the
hypothalamus (VMH), area tegmentalis ventralis (VTA),
substantia nigra (SN), and the neuroendocrine systems (26).
Consisting of nine amino acids, this neuropeptide is produced by
PVN and SON. Through axonal transport OT is centrally
released to hippocampus, amygdala, striatum, hypothalamus,
nucleus accumbens, and the central brain in response to social
interactions and stressors (27–30). In line with the Calm and
Connect Model (31), which assumes that bonding, experienced
through touch and social affection, leads to OT production and
thus positively reinforces social connection, several studies have
linked insecure attachment patterns to impairments of the OT-
system (23, 27, 29, 32).g 2In the context of addiction, beneficial effects of administered
OT on drug tolerance, withdrawal and seeking have been
proposed across various substance classes (33, 34). Individual
differences in the endogenous OT-system may therefore affect
the vulnerability to addiction. SUDs have been repeatedly linked
to decreased levels of OT (35–37). Furthermore, OT is assumed
to modulate the mesolimbic dopamine system (38), a structure
which is substantially involved with the process of addiction
development and bond formation (2, 39). Similarly, there is
considerable evidence suggesting interactions between the OT
and endogenous opioid system (40). In line with these
observations, a recent review by Zanos et al. (41) concluded
that the OT system is not only meaningfully influenced by opioid
addiction and abstinence but also might serve as a critical target
for pharmacological interventions. Such findings inform the first
aim of this study to investigate cross sectional relationships
between substance use and OT levels.
Previous research indicated a relationship between the
administration of stimuli designed to activate the attachment
system of participants and the OT-system. One such measure,
the Adult Attachment Projective Picture System (AAP) was
shown to significantly increase OT levels (42). This study was
conducted with a sample of healthy lactating mothers who might
be thought to be especially responsive to attachment cues.
Moreover, these authors hypothesized that women with more
secure attachment patterns should show higher OT-reactivity.
However, in this study, the authors were not able to confirm the
proposed association between a larger increase in OT and more
securely attached mothers. This experimental paradigm using
the AAP as an attachment stimulus is adopted in the current
study, while our study is focused on substance users compared to
healthy controls (HCs).
What is more, in recent years, several reviews have been
published which critically asses methodical flaws frequently
observed within the research of the human OT system [e.g.,
(43–45)]. These contributions specifically emphasize the
importance targeted hypotheses, consideration of differences
between central processing of OT and its peripheral levels, as
well studies focussed on peripheral levels making use of plasma
samples, and plasma to be assayed for OT levels after extraction.
With this in mind, this study aimed to enhance the
understanding the relationship between attachment and the OT-
system in patients with SUD. We sought to address two primary
aims. First, using baseline levels of peripheral OT, we examined
their associations with substance use (using the ASSIST),
attachment (using the Adult Attachment-Scale), and current
symptoms (using the Brief Symptom Inventory). In relation toSeptember 2020 | Volume 11 | Article 460506
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with insecure attachment patterns and psychopathological
symptom burden in the PUD group. Our second aim follows the
experimental study by Krause et al. (42), which focuses on the
response of the peripheral OT-system in response to an attachment-
related stimulus. In the experimental study, we compared PUD
patients undergoing maintenance therapy to HCs. Following
Krause, we expected to see a rise in the OT levels of health
controls when exposed to an attachment stimulus. We were
exploring whether the SUD group would show a different OT
response to the same stimulus. However, as this is the first time, this
experimental paradigm is investigated in patients undergoing
maintenance treatment, this hypothesis remains exploratory.SAMPLE AND METHODS
Participants
The study sample consisted of 48 male participants between 19 to
38 years of age (M = 27.42, SD = 4.82), consisting of one clinical
(PUD; n = 24) and one non-clinical group (HC; n = 24).
Participants in the clinical group met diagnostic criteria for
PUD (F19.2), diagnosed according to the International
Classification of Diseases version 10 (ICD 10) (46) by a
licensed psychiatrist. Due to the haphazard drug use, one of
the main characteristics for PUD, the drugs consumed cannot be
reported in detail. At the time of the study, all PUDs were
currently participating in maintenance therapy as described
below. PUDs with fluid psychotic symptoms were excluded.
Comorbidities with other diagnoses were distributed as follows:
9.2% Affective disorders (F3.x), 5.8% Neurotic, stress and
somatoform disorders (F4.x), 4.6% Personality and behavioral
disorders (F6.x), 2.3% Schizophrenia, schizotypal and delusional
disorders (F2.x), 1.2% Behavioral and emotional disorders (F5.x)
with onset usually occurring in childhood and adolescence.
Before participating in the study PUD patients had been in
maintenance therapy for a mean time of 15 weeks (SD = 13.8) and
received either Levo-Methasan (n = 21), Bupensan (n = 1), Substitol
Retard (n = 1), or Compensan Retard (n = 1) as a substitution agent,
with daily doses ranging from 2 to 320 mg, depending on patient
and medication. Furthermore, 21 PUD patients received additional
psychopharmacological medication: 16 (66.67%) received
antipsychotics and 19 (79.17%) received antidepressants.
Participants of the non-clinical group, exclusively non-smoking
men, reported either none or just a few previous experiences with
illegal substances. With the exception of occasional consumption of
alcohol, no use of psychoactive substances was reported by HC in
the last 30 days prior to the investigation and no use of
psychopharmacological medication. HCs were included if they
reported no past or present psychiatric disorder or chronic disease.
Exclusion criteria for both groups were insufficient knowledge
of the German language. Clinical subjects were assessed at the
Johnsdorf therapeutic facility of the Grüner Kreis Society. Non-
clinical subjects were recruited through advertising on social
networks and via email distribution of the University of Graz.
The study was approved by the ethics committee of theFrontiers in Psychiatry | www.frontiersin.org 3University of Graz, Austria and conducted in accordance with
the Declaration of Helsinki.
Procedure and Design
In order to eliminate any effects due to circadian rhythms the
timing of the experiment was standardized. Participants were
asked to fast for at least 3 hours before arriving in the
laboratory (between 12.00 am and 3.30 pm), avoid caffeinated
drinks and to refrain from smoking on the day of participation,
before and during the experiment. After written informed consent
was obtained and the subjects were notified about the course of the
experiment, the first venipuncture and blood collection was
performed. Immediately after, the AAP (47) was applied in
which participants were asked to tell a story for each of the
eight shown pictures with either monadic or dyadic scenes by
answering the following questions: “What is happening in the
scene?”, “What led up to the scene?”, “What are the characters
thinking or feeling?”, and “What might happen next?”. The
abstract line drawings indicate scenarios such as illness,
separation, and abuse without detailed facial expression, allow a
large scope of interpretation (47). The AAP measure is designed
around a common assumption in observational and discourse
attachment measures that attachment behavior is best observed
directly after an attachment related stimulus is delivered or
represented such as a separation, loss, illness and so on (48).
The interviews lasted on average 16 min (SD = 4.50). The AAP
interviews were administered by a trained psychologist in a
standardized manner according to the published administration
requirements. Following the AAP, and 25 min after the first blood
sample a second blood sample was collected, again via
venipuncture. The psychometric assessment (described below)
took place online via Lime-Survey® before the experiment.
Measures
Addictive Behavior
The German Version of the Alcohol, Smoking and Substance
Involvement Screening Test [ASSIST 3.0; (49), German Version;
(50)] is a structured short interview designed to record life-
time consumption behavior and its negative effects from the
following substance classes: alcohol, tobacco, cannabis, cocaine,
amphetamines, inhalants, sedatives, hallucinogens, and opiates
among others. For this study, the interview was adapted as a self-
report questionnaire. Questions about the “Frequency of drug use”,
“Craving to use the drug”, “Problems”, and “Failed expectations”
are rated on a 7-point Likert scale from 0 (never) to 6 (daily).
Questions about “Expressed concerns by relatives or friends”,
“Failed attempts to cut down drug use”, and “Drug injection” are
rated on a 3-point Likert scale (0 = “no never”, 3 = “yes, but not in
the past 3 months”, 6 = “yes, in the past 3 months”). By adding the
drug specific symptom scores an overall score for every symptom
class (mentioned above), as well as a total score was calculated.
Subscales ranged in Cronbach’s alpha from 0.79 to 0.89.
Mental Health Symptoms
The short version of the Brief Symptom Inventory [BSI-18; (51),
German Version: (52)] assesses the amount of psychiatric
burden of the last 7 days by means of 6 items on each of theSeptember 2020 | Volume 11 | Article 460506
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Anxiety. It is rated on a 5-point Likert scale from 0 “absolutely
not” to 4 “very strong”. A Global Severity Index (GSI) can be
generated for a total of the 18 items. Cronbach’s alpha for the
subscales ranged from 0.70 to 0.87. The total Global Severity
Index score showed a Cronbach’s alpha of 0.87.
Attachment Styles
The German Version of the Adult Attachment Scale [AAS; (53,
54)] is a self-report method measuring attachment dimensions
based on attachment theory (55). This questionnaire consists of
three subscales: (1) Anxiety about being rejected or unloved, (2)
Comfort with Closeness and Intimacy, and (3) Comfort in
Depending on others. This questionnaire consists of 18 items
rated on a 5-point Likert scale ranging from 1 (strongly disagree)
to 5 (strongly agree). Cronbach’s alpha for the scales ranged from
0.68 for to 0.79.
Oxytocin Assessment
For measuring the plasma OT levels, blood samples were drawn
from antecubital veins into 3-ml vacutainer blood vacuettes
(Greiner Bio-One International GmbH, Austria) containing
Aprotinin (500 KIU/ml of blood) (Sigma-Aldrich, Germany).
Vacuettes were stored at −20°C before use. Vacuettes were
centrifuged at 4°C at 1.600 g for 15 min. Supernatants were
stored at −80°C until analysis. Extraction of samples was
undertaken and OT concentrations in the extracts were
determined in duplicate by Oxytocin ELISA kit (ADI-900-
153A, Enzo Life Sciences, USA), a colorimetric competitive
enzyme immunoassay kit at the Center for Medical Research at
the Medical University Graz, Austria. The mean intra-assay and
inter-assay coefficients of variability were 23.4% and 13.9%,
respectively; sensitivity was 15.0pg/ml. All procedures were
performed according to the manufacturer’s instructions by
authorized personnel.
Data Reduction and Statistical Analyses
For group comparisons in the experimental design, one-way
analyses of variance and c² tests were conducted. To evaluate
the reactivity of OT, the amount of the difference value of pre- and
post-OT-level was considered. To investigate the relationship
between OT and behavioral measures Pearson’s correlation
coefficients were calculated separated for the PUD group. Alpha
was set to p < 0.05 in ANOVAs and Pearson’s correlations.
However, with regard to recent critical reviews of OT-literature
[e.g., (43, 44)], we additionally corrected for multiple comparisons
via the Bonferroni correction. In order to ensure a better
evaluation of the results, effect sizes were included.RESULTS
Demographics and Clinical Characteristics
Socio-demographic variables, scores for addictive behavior as
well as requirements prior to the interview of both groups are
presented in Table 1.Frontiers in Psychiatry | www.frontiersin.org 4Hypothesis-Testing Results
Group Differences in OT and Attachment
As depicted in Table 2, group comparisons showed that
PUD had higher levels of OT compared to HC before at
baseline (F(1, 46) = 7.02; p < 0.05). No other significant group
differences regarding OT were observed (all p > 0.05) [for
comparative means see (56)]. Following the administration of
the AAP as attachment stimuli, the HC seemed to increase in OT
levels whereas the PUD group’s OT remained flat. However, this
difference was not significant (F(1, 46) = 3.25; p = 0.08).
Furthermore, the between group tests for differences in the
measures of mental health and attachment the PUD group
showed a tendency toward less Comfort with closeness
(F(1, 46) = 3.97; p = 0.05) and Comfort with Depending on
others (F(1, 46) = 3.61; p = 0.06) and higher depressive symptom
burden (F(1, 46) = 8.27; p < 0.05). With regard to the Bonferroni
corrected alpha level, no group differences remained significant
(all p > 0.003)
Intercorrelations of Oxytocin, Attachment,
and Personality Characteristics for PUD
Correlations over PUD showed that baseline OT-levels were
related to less Comfort with closeness (r = −0.41, p < 0.05) and
lifetime substance use over all substance classes (r = −.48, p <
0.05). Furthermore, OT-reactivity showed non-significant
tendencies with Comfort with closeness (r = .34, p < 0.10) and
Lifetime substance use (r = .37; p = 0.07). Moreover, as shown in
Table 3, insecure attachment patterns were related to Depression
(r = −.51–.49; all p < 0.05). No correlation remained significant if
corrected for multiple comparisons (all p > 0.003).DISCUSSION
In order to enhance the understanding of the relationship of OT
to SUD, we investigated the differences in psychopathology,
attachment, and the OT-system between PUD patients
undergoing maintenance treatment compared to HC, as well as
differences in peripheral OT response to an attachment-related
stimulus. Our results suggest that PUD patients were higher OT
at baseline compared to a HC group. In response to the
attachment stimulus containing the AAP procedure, differences
between the PUD and HC groups regarding OT-reactivity
remained non-significant. Furthermore, baseline OT-levels
showed a significant relationship with decreased Comfort with
closeness in PUD patients.
However, these results should be interpreted with caution. In
the first instance, the sample size of the study was small and there
were numerous significance tests run. Following Nave et al. (44)
and McCullough et al. (43), who proposed the necessity for
correcting for multiple comparisons, no finding remained
significant based on a Bonferroni corrected alpha level. While
the Bonferroni correction has been criticized as being overly
conservative (57, 58), the findings of this study are tentative and
require replication in a larger study.September 2020 | Volume 11 | Article 460506
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contrast to many other studies (41). The interpretation of this result
needs to remain speculative at this point. However, it is conceivable
that this finding might be traced back to the characteristics of livingFrontiers in Psychiatry | www.frontiersin.org 5in the therapeutic community which is characterized by high social
cohesion and an attachment focused treatment approach (59).
Furthermore, in contrast to the HC group, PUD participants
traveled to the OT measuring in groups, which might haveTABLE 1 | Group differences in demographic data and conditions prior to investigation.
PUD (n = 24) HC (n = 24) T df p
M SD M SD
Age 28.50 5.85 26.33 3.25 -1.59 35.99 0.119
Risk of substance use
Lifetime substance use (incl. alcohol & tobacco) 23.63 4.79 8.63 4.18 -11.56* 45.17 0.000
Global continuum of substance risk (incl. alcohol & tobacco) 29.04 4.43 13.75 7.04 -9.01 46 0.000
Conditions day of examination
Waking up 467.17 79.61 371.96 138.38 -2.92* 46 0.005
Caffeine consumptiona 440.63 178.57 – – – – –
Nicotine consumptiona 103.54 195.23 – – – – –
Last meala 272.63 133.84 360.04 256.75 1.48 34.64 0.146
Sexual activity 700.43 138.25 621.25 231.45 -1.43 37.83 0.161
PUD (n = 24) HC (n = 24) X² df p




































Psychiatric diagnosis 45.15* 1 0.000
Yes 24 0
Current psychotherapy 49.00* 1 0.000
Yes 24 0
Chronic physical health problems 3.33 1 0.068
Yes 3 0
Regular medication 49.00* 1 0.020
Yes 24 0September 2020 | Volume 11 | Article 4*p < 0.05; PUD, Poly-drug use disordered patients; HC, Healthy controls. aPast time in minutes since last consumption on test day.TABLE 2 | Group differences (ANOVA) in behavioral and biological measures.
Measures a PUD (n = 24) HC (n = 24) F (1, 46) h² p
M SD M SD
BSI-18
Somatization 0.690 2.17 2.73 2.13 2.35 0.00 0.00 0.955
Depression 0.852 6.25 5.57 2.71 2.33 8.27* 0.15 0.006
Anxiety 0.816 4.54 5.01 3.46 2.41 0.91 0.02 0.344
Total Score 0.869 12.96 11.14 8.71 5.39 2.83 0.06 0.099
Oxytocin
Pre (pg/ml) 60.64 24.87 44.74 15.68 7.02* 0.13 0.011
Post (pg/ml) 60.38 17.25 60.46 38.73 0.00 0.00 0.992
Reactivity -0.26 17.64 15.72 39.66 3.25 0.06 0.078
AAS
Dependence 0.731 16.13 4.89 18.42 3.31 3.61 0.07 0.064
Closeness 0.786 11.63 3.93 13.92 4.03 3.97 0.08 0.052
Anxiety 0.678 12.29 3.91 12.29 3.75 0.00 0.00 1.000Bonferroni corrected p = 0.005; *p < 0.05; PUD, Poly-drug use disordered patients; HC, Healthy controls; Pre, baseline OT-levels; Post, OT-levels after confrontation with attachment
related cue.60506
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possibility would be an influence of the various medications used
for maintenance therapy which interact with the opioid system, or
indeed the use of antidepressant or antipsychotic medications in
PUD participants. However, while not extensively researched,
recent literature indicates no influence of antidepressant
pharmacological treatments on OT (61) but there have been
some animal studies suggesting a relationship between
antidepressants and OT metabolism (62).
OT-reactivity in PUD patients did not significantly differ from
variability of HC participants. Based on previous research it might
be speculated (29, 42), that an increase in OT in response to an
attachment related stimulus is associated with seeking and finding
of an internalized positive attachment representation.
Furthermore, animal research has shown that the administration
of morphine potently inhibits the secretion of OT and depresses
the OT-sensitivity of the mammary gland, due to inhibition of the
firing of supraoptic OT-neurons (63–66). Considering potential
ceiling effects of methadone on the endogenous OT-system, its
chronic administration could cause a maximum release of OT, so
that further increases in OT are diminished, regardless of whether
the person is triggered with an attachment related stimulus or not.
Regarding the statistical tendencies observed in our sample which
hints in the direction described above, more data is needed to
further evaluate this line of interpretation.
Contradicting recent literature (15, 67), no significant
differences between PUD patients and HC were found
regarding adult attachment attitude using the AAS measure.
Nevertheless, the non-significant associations showed there may
be important relationships here which the current study was
underpowered to detect and are consistent with the pattern
observed in previous research (14, 67–69).
In general, the main results in this study may be influenced by
several effects brought about by a combination of psychopharmacology,
maintenance, and long-term psychotherapeutic treatment.
In addition, our findings designate a negative relationship
between baseline OT-level and Comfort with Closeness in PUD
patients. Corresponding to recent findings by Torres et al. (70),
which suggested a negative correlation between the dose of
maintenance therapy and Closeness as well as decreased Anxiety
in patients undergoing maintenance therapy. Therefore, the
mechanism of maintenance therapy might operate on the surfaceFrontiers in Psychiatry | www.frontiersin.org 6but helps PUD patients only to a limited extent in the formation of
healthy interpersonal relationships and positive attachment
representations that can be relied on in times of distress (15, 21).
Moreover, we observed tentative hints toward a link between
OT-reactivity and increased Comfort with closeness which,
however, did not achieve statistical significance. Similarly,
Krause et al. (42) did not find significant associations between
attachment security and OT-reactivity in lactating mothers.
Hence, while a relationship between attachment and OT-
reactivity may be a reasonable premise, more research should
be done to further analyse this subject matter.
Limitations and Future Perspectives
Findings of the present study are mainly limited by the sample
size, the exclusion of the female gender and the use of self-report
measures. Furthermore, the measurement of OT is controversially
discussed in literature (43, 71).
Furthermore, nicotine abstinence was not given in PUD patients
prior to the investigation in this study, which might be seen as a
characteristic of PUD patients in maintenance treatment. However,
in line with previous research, nicotine abuse was not related to OT
(72, 73). Moreover, due to the explorative nature of this study, no
control condition was administered, which limits the interpretability
of the effects of the AAP on OT-levels. This shortcoming needs to be
addressed in future studies. What is more, a recent study by
Fuchshuber et al. (74) indicated a medium effect size regarding the
difference in attachment security comparing PUD and HC groups
(74).With respect to the relatively small sample size employed in this
study, future research addressing this subject might take this to an
account regarding the estimation of the required sample size. Along,
to gain a more complete understanding of the relationship between
attachment, OT and maintenance treatment, the investigation of
abstinent SUD patients who are not undergoing maintenance
therapy is of interest for future studies. Finally, cortisol and
vasopressin, both known for their close interrelatedness with OT,
should be taken into account (29, 30, 75, 76).CONCLUSION
This study suggests that peripheral OT levels in poly-drug users
undergoing maintenance treatment do not show significantTABLE 3 | Intercorrelations for behavioral and biological measures for PUD (n = 24).
Variable 1 2 3 4 5 6 7 8 9 10 11
1. BSI-18 Somatization .40 .79** −.21 −.03 .27 −.11 −.15 .19 .17 .14
2. BSI-18 Depression .48* −.04 .01 .06 −.51* −.46* .49* .21 .21
3. BSI-18 Anxiety −.13 −.08 .10 −.02 −.12 .22 .14 .34
4. OT Pre .70** −.72* .05 −.41 −.37 −.48* .11
5. OT Post −.02 .07 −.24 −.33 −.31 −.04
6. OT Reactivity .00 .34 .20 .37 −.19
7. AAS Dependence .68** −.36 −.05 −.20
8. AAS Closeness −.02 −.04 −.22
9. AAS Anxiety −.18 .24
10. ASSIST Lifetime SU −.16
11. ASSIST GC of SRSeptember 2020 | Volume 11 | Article 46N = 24; Bonferroni corrected p = 0.004; **p < .01, *p < .05; Pre, baseline OT-levels; Post, OT-levels after confrontation with attachment related cue; GC, global continuum; SU, substance
use; SR, substance risk.0506
Fuchshuber et al. Oxytocin Reactivity in Poly-Drug Usedifferences regarding responsive to an attachment related
stimulus delivered via the Adult Attachment projective task
compared to HCs. The meaning of this finding is complicated
by a number of confound in the PUD group related to both the
pharmacological and psycho-social treatments they are
receiving. The current findings which indicate non-significant
tendencies however are an important preliminary finding which
we hope will motivate more research using an experimental
paradigm to further explore this hypothesis.DATA AVAILABILITY STATEMENT
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